SCHEMBL328910

SCHEMBL328910

CC1(C)C(=O)N(C2C3CCCC2CC(C(=O)O)C3)CC1COc1ccc(C#N)cn1

nearest known ligand 0.86

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 15/20 0.86
HSD11B2 P80365 9/20 0.86
CYP2D6 P10635 1/20 0.37
DPP4 P27487 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP9 Q86TI2 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
TACR3 P29371 3/20 0.36
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL328938 0.92 HSD11B1 (1.00) HSD11B1HSD11B2CYP2D6DPP4DPP8
SCHEMBL328817 0.92 HSD11B1 (0.83) HSD11B1HSD11B2CYP2D6DPP4DPP8
SCHEMBL328942 0.82 HSD11B1 (0.86) HSD11B1HSD11B2CYP2D6
SCHEMBL328846 0.80 HSD11B1 (0.85) HSD11B1HSD11B2CYP2D6DPP4DPP8
SCHEMBL4995227 0.80 HSD11B1 (0.81) HSD11B1HSD11B2CYP2D6DPP4DPP8
SCHEMBL2716665 0.80 HSD11B1 (0.81) HSD11B1HSD11B2CYP2D6DPP4DPP8
SCHEMBL2720258 0.80 HSD11B1 (0.81) HSD11B1HSD11B2CYP2D6DPP4DPP8
SCHEMBL19256171 0.80 HSD11B1 (1.00) HSD11B1HSD11B2CYP2D6
SCHEMBL4791837 0.80 HSD11B1 (1.00) HSD11B1HSD11B2CYP2D6
SCHEMBL4791839 0.80 HSD11B1 (1.00) HSD11B1HSD11B2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007719-B1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LAB (US) 2012-05-02 EP disclosed
EP-2407452-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme Abbott Laboratories (US) 2012-01-18 EP disclosed
US-7737137-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2010-06-15 US disclosed
US-20080312214-A1 Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme ABBOTT LABORATORIES (US) 2008-12-18 US disclosed
US-7435833-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2008-10-14 US disclosed
US-20080076819-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076819-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885HSD11B2 2/4885CYP2D6 182/4885
US-20080312214-A1 Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885CYP2D6 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.